Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors

AIDS

Volumn 25, Issue 3, 2011, Pages 385-387

  Salgado, Maria ^a   Kirk, Gregory D ^a   Cox, Andrea ^a   Rutebemberwa, Alleluiah ^a   Higgins, Yvonne ^a   Astemborski, Jacquie ^a   Thomas, David L ^a   Thio, Chloe L ^a   Sulkowski, Mark S ^a   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B;

AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CONTROL; GENE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

AFRICAN AMERICANS; GENOTYPE; HEPACIVIRUS; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKINS; VIRAL LOAD;

EID: 79551578079     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328341b86a     Document Type: Article

References (12)

1. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
2. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461:399-401.
3. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
4. Blankson JN. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res 2010; 85:295-302.
5. Baker BM, Block BL, Rothchild AC, Walker BD. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009; 9:55-69.
6. Migueles SA, Connors M. Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 2010; 304:194-201.
7. Sajadi MM, Shakeri N, Talwani R, Redfield RR. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2010; 24:1689-1695.
8. Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guergnon J, et al. Spontaneous control of viral replication during primary HIV infection: when is 'HIV controller' status established? Clin Infect Dis 2009; 49:982-986.
9. Martin MP, Ying Q, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine hepatitis B or HIV outcomes. J Infect Dis (in press).
10. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-CwM04 and hepatitis C virus persistence. J Virol 2002; 76:4792-4797.
11. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001; 62:1009-1030.
12. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86:655-661.